+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cluster Of Differentiation 3"

CAR T-cell Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CAR T - Cell Therapy - Competitive landscape, 2023 - Product Thumbnail Image

CAR T - Cell Therapy - Competitive landscape, 2023

  • Report
  • April 2023
  • 500 Pages
  • Global
From
CD3 antigen inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

CD3 antigen inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CD 3 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CD 3 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Anti-CD3 Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD3 Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2024 - Product Thumbnail Image

T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Bispecific antibody - Competitive landscape, 2023 - Product Thumbnail Image

Bispecific antibody - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034

  • Report
  • March 2024
  • 200 Pages
  • Global
From
From
Retinoblastoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Retinoblastoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 72 Pages
  • Global
From
Market Spotlight: Neuroendocrine tumors (NET) - Product Thumbnail Image

Market Spotlight: Neuroendocrine tumors (NET)

  • Report
  • May 2021
  • 42 Pages
  • Global
Loading Indicator

The Cluster of Differentiation 3 (CD3) market is a subset of the oncology drug market that focuses on drugs that target the CD3 molecule. CD3 is a protein found on the surface of T-cells, which are a type of white blood cell that plays a key role in the body's immune system. CD3-targeting drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. These drugs work by blocking the CD3 molecule, which prevents the T-cells from attacking healthy cells and helps to reduce the growth of cancer cells. Some of the companies in the CD3 market include Novartis, Merck, Pfizer, and Bristol-Myers Squibb. These companies have developed a range of CD3-targeting drugs, including Imbruvica, Keytruda, and Opdivo. These drugs have been approved by the FDA for the treatment of various types of cancer and are widely used in the oncology field. Show Less Read more